Isofol Medical AB announces publication of a study comparing the concentration of folate metabolites in tumor, mucosa, and plasma of patients with colon cancer after administration of Modufolin® or Isovorin® (levo-‐ leucovorin). The results support Isofol’s belief that Modufolin® has the potential to increase the efficacy of 5-‐fluorouracil-‐based chemotherapy for many patients. Results clearly demonstrated that Modufolin® administration resulted in significantly higher methylenetetrahydrofolate levels than Isovorin® administration. Isofol will continue to evaluate the potential of Modufolin® as a substitute to Isovorin® in the treatment of patients with colon cancer.
The publication entitled “A pharmacokinetic and pharmacodynamic investigation of Modufolin® compared to Isovorin® after single dose intravenous administration to patients with colon cancer: a randomized study” is published in Cancer Chemotherapy and Pharmacology and is available online via PubMed at:http://www.ncbi.nlm.nih.gov/pubmed/25342290.
Modufolin®(chemical name [6R]-‐5,10-‐methylenetetrahydrofolate), is a novel folate-‐based compound developed to increase the efficacy and reduce the side effects of antimetabolites used in cancer treatment. It is the key active metabolite of all clinically used folate-‐based drugs today including Leucovorin and Levoleucovorin and therefore does not require metabolic activation. This makes Modufolin® suitable for all patients irrespective of their capacity to activate folates and it is currently evaluated in clinical phase II studies.
About Isofol Medical AB
Isofol Medical is a clinical stage pharmaceutical company developing novel products for unmet needs within oncology. Isofol’s lead clinical candidate is Modufolin®. Isofol Medical collaborates closely with its strategic R&D partner Merck Millipore, the world’s leading manufacturer of reduced folates including Leucovorin and Levoleucovorin.
For more information, please contact:
Anders Rabbe, CEO, Isofol Medical AB
E‐mail: email@example.com; Phone: +46 (0)707 646 500
Modufolin® is a registered Trademark of Merck KGaA, Darmstadt, Germany.